Gilead Sciences Inc (GILD)
111.44
-1.91
(-1.68%)
USD |
NASDAQ |
Mar 14, 16:00
111.50
+0.06
(+0.05%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 138.78B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 55.74% |
| Valuation | |
| PE Ratio | 301.19 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.875 |
| Price to Book Value | 7.180 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.79 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.382 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 38.10% |
Profile
Edit
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
| URL | https://www.gilead.com |
| Investor Relations URL | https://investors.gilead.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 24, 2025 |
| Last Earnings Release | Feb. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2025 |
Ratings
Profile
Edit
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
| URL | https://www.gilead.com |
| Investor Relations URL | https://investors.gilead.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 24, 2025 |
| Last Earnings Release | Feb. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2025 |